Should benefit from an industry fat with companies that need clinical trials for newly developed treatments.
Although the biopharmaceutical services industry looks strong going forward, KNDL has a lower ROE (5.5%) than I'm happy with. Their decision to take on $198 million in debt in 2006 is worrying. This move raised their current liabilities to a level… More